Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAW NASDAQ:JNP NASDAQ:NEXI NASDAQ:NTHI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.00$0.01$0.06▼$0.33N/AN/A34,287 shsN/AJNPJuniper Pharmaceuticals$11.50$0.00$4.30▼$13.25N/AN/A155,873 shs28,513 shsNEXINexImmune$0.00$0.00$0.00▼$1.18N/A2.046,143 shsN/ANTHINeonc Technologies$5.82+0.9%$4.88$3.20▼$25.00N/AN/A155,841 shs45,530 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%+50.00%-72.14%-89.97%JNPJuniper Pharmaceuticals0.00%0.00%0.00%0.00%0.00%NEXINexImmune0.00%0.00%+100.00%+100.00%-99.98%NTHINeonc Technologies0.00%+13.67%+23.83%-19.39%+581,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AJNPJuniper Pharmaceuticals 0.00N/AN/AN/ANEXINexImmune 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/ANTHINeonc Technologies$59.99KN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ANEXINexImmune-$32.34M-$18.54N/A∞N/AN/A-534.32%-213.72%N/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/ALatest JNP, AEHAW, NTHI, and NEXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NTHINeonc TechnologiesN/A-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEHAWAesther Healthcare AcquisitionN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/AN/ANEXINexImmuneN/A0.660.66NTHINeonc TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AJNPJuniper Pharmaceuticals45.56%NEXINexImmune9.85%NTHINeonc TechnologiesN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AJNPJuniper Pharmaceuticals7.20%NEXINexImmune14.90%NTHINeonc TechnologiesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableJNPJuniper PharmaceuticalsN/AN/AN/AOptionableNEXINexImmune61.40 million1.19 millionNot OptionableNTHINeonc Technologies8N/AN/AN/AJNP, AEHAW, NTHI, and NEXI HeadlinesRecent News About These CompaniesNeOnc Technologies reports Q2 EPS (30c) vs (27c) last yearAugust 19, 2025 | msn.comNeOnc Technologies Holdings, Inc.: NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational UpdateAugust 19, 2025 | finanznachrichten.deNeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational UpdateAugust 19, 2025 | finance.yahoo.comNew to The Street’s Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 14, 2025 | freep.comFNeOnc Technologies Expands with NuroMENA Holdings IncorporationAugust 14, 2025 | msn.comNew to The Street's Esteemed Client NeOnc Technologies Finalizes $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 11, 2025 | eagletribune.comENeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM IncorporationAugust 11, 2025 | globenewswire.comNeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and LeukemiaAugust 7, 2025 | globenewswire.comNTHI - NeOnc Technologies Holdings Inc Financials | MorningstarAugust 6, 2025 | morningstar.comMNeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain CancerAugust 4, 2025 | globenewswire.comNeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of DirectorsJuly 30, 2025 | globenewswire.comNeOnc Technologies Holdings, Inc.: NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finanznachrichten.deNeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar InvestmentJuly 30, 2025 | finance.yahoo.comAI and biotech take on brain cancerJuly 30, 2025 | finance.yahoo.comNeOnc Technologies to Participate at the BTIG Virtual Biotechnology ConferenceJuly 28, 2025 | tmcnet.comNeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar InvestmentJuly 24, 2025 | finance.yahoo.comNeOnc Technologies’ Executive Chairman to Be Featured in Live Interview with Kenny Polcari on ...July 24, 2025 | bakersfield.comBCORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.July 23, 2025 | globenewswire.comNeOnc Technologies Secures Board Approval for $50 Million Strategic ...July 12, 2025 | seekingalpha.comNeOnc Technologies Holdings, Inc. Secures Board Approval for ... - NasdaqJuly 12, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJNP, AEHAW, NTHI, and NEXI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0039 0.00 (0.00%) As of 08/15/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Juniper Pharmaceuticals NASDAQ:JNPJuniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts.NexImmune NASDAQ:NEXI$0.0002 0.00 (0.00%) As of 08/22/2025NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Neonc Technologies NASDAQ:NTHI$5.82 +0.05 (+0.87%) As of 08/22/2025 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Workday: Institutions Are Buying This Stock, Shouldn’t You? Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access